...
首页> 外文期刊>British Journal of Cancer >3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells
【24h】

3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells

机译:3- [211At] astato-4-氟苄基胍:一种可能被神经母细胞瘤细胞长时间保留的治疗剂

获取原文

摘要

An analogue of meta-iodobenzylguanidine (MIBG) in which an aromatic hydrogen was replaced with fluorine has been found to possess many properties similar to those of the parent compound. Moreover, 4-fluoro-3-iodobenzylguanidine (FIBG) was retained in vitro by human neuroblastoma cells to a much greater extent than MIBG itself. Since alpha-emitters such as 211At could be valuable for the treatment of micrometastatic disease, an FIBG analogue in which the iodine atom is replaced by 211At would be of interest. In this study, we have evaluated the in vitro and in vivo properties of 3-[211At]astato-4-fluorobenzylguanidine ([211At]AFBG). The specific binding of [211At]AFBG to SK-N-SH human neuroblastoma cells remained fairly constant over 2- to 3-log activity range and was similar to that of [131I]MIBG. The uptake of [211At]AFBG by this cell line was reduced by desipramine, ouabain, 4 degrees C incubation, noradrenaline, unlabelled MIBG and FIBG, suggesting that its uptake is specifically mediated through an active uptake-1 mechanism. Over the 16 h period studied, the amount of [211At]AFBG retained was similar to that of [131I]FIBG, whereas the per cent of retained meta-[211At]astatobenzylguanidine ([211At]MABG) was considerably less than that of [131I]FIBG (53% vs 75%; P < 0.05). The IC50 values for the inhibition of uptake of [131I]MIBG, [211At]MABG, [125I]FIBG and [211At]AFBG by unlabelled MIBG were 209, 300, 407 and 661 nM respectively, suggesting that the affinities of these tracers for the noradrenaline transporter in SK-N-SH cells increase in that order. Compared with [211At]MABG, higher uptake of [211At]AFBG was seen in vivo in normal mouse target tissues such as heart and, to a certain extent, in adrenals. That the uptake of [211At]AFBG in these tissues was related to the uptake-1 mechanism was demonstrated by its reduction when mice were pretreated with desipramine. However, the stability of [211At]AFBG towards in vivo dehalogenation was less than that of [211At]MABG, as evidenced by the higher uptake of 211At in thyroid, spleen, lungs and stomach.
机译:已经发现其中芳族氢被氟取代的间碘苄基胍(MIBG)的类似物具有许多类似于母体化合物的性质。此外,人成神经细胞瘤细胞在体外保留4-氟-3-碘苄基胍(FIBG)的程度比MIBG本身大得多。由于诸如211At的α发射体对于治疗微转移性疾病可能很有价值,因此其中碘原子被211At取代的FIBG类似物将是令人感兴趣的。在这项研究中,我们评估了3- [211At] astato-4-氟苄基胍([211At] AFBG)的体外和体内特性。 [211At] AFBG与SK-N-SH人成神经细胞瘤细胞的特异性结合在2到3对数的活性范围内保持相当恒定,与[131I] MIBG相似。地昔帕明,哇巴因,4°C孵育,去甲肾上腺素,未标记的MIBG和FIBG降低了该细胞系对[211At] AFBG的吸收,这表明它的吸收是通过一个主动的upup-1机制专门介导的。在研究的16小时内,保留的[211At] AFBG的量与[131I] FIBG相似,而保留的间位[211At] astato苄基胍([211At] MABG)的百分比显着小于[131] 131I] FIBG(53%对75%; P <0.05)。未标记的MIBG抑制[131I] MIBG,[211At] MABG,[125I] FIBG和[211At] AFBG吸收的IC50值分别为209、300、407和661 nM,表明这些示踪剂对SK-N-SH细胞中去甲肾上腺素转运蛋白以该顺序增加。与[211At] MABG相比,在正常小鼠目标组织(例如心脏)和一定程度上在肾上腺中观察到更高的[211At] AFBG吸收。当用地昔帕明预处理小鼠时,[211At] AFBG在这些组织中的摄取与摄取-1的机制有关,这可通过其减少来证明。然而,[211At] AFBG对体内脱卤的稳定性低于[211At] MABG的稳定性,这是由于211At在甲状腺,脾脏,肺和胃中的摄取较高所证明的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号